MYL Related Analyst EPS View

May 3, 2013 12:21 PM Mylan (MYL) Still a Strong Buy at Needham & Company

Jul 27, 2012 02:47 PM Canaccord Genuity Maintains a 'Hold' on Mylan (MYL); Raising PT on Solid Q2

Jul 27, 2012 10:51 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Continuing to Grind Out Upside

Jul 24, 2012 04:52 PM Barclays Maintains an 'Overweight' on Mylan (MYL); Q2 Preview: Expected Mixed Results

Jul 20, 2012 08:31 AM Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

Jun 26, 2012 11:05 AM UBS Defends Momenta Pharmaceuticals (NASDAQ: MNTA); Negative News Largely In Stock

Jun 26, 2012 07:40 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Brushing Off Generic Copaxone Loss

May 10, 2012 11:11 AM Canaccord Genuity on Specialty Pharma: TEVA's Q1 Effect on Specialty Pharma (TEVA, WPI, PRGO & MYL)

May 1, 2012 08:26 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Chalk One Up in the PIV Win Column As Doryx Goes Generic

Apr 10, 2012 01:26 PM UBS on U.S. Pharma - Large Cap and Specialty: Q1 Preview - Off to a Good Start

Apr 9, 2012 02:10 PM Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX

Apr 4, 2012 11:23 AM Canaccord Genuity on Life Sciences/Specialty Pharma: What an Actavis Deal Could Mean to Watson (WPI) and the Sector

Feb 22, 2012 10:08 AM Canaccord Genuity Maintains a 'Hold' on Mylan (MYL); Analyst Day Big on Detail, Small on Guidance Surprise